CLOs on the Move

Abengoa Bioenergy Corporation

www.abengoabioenergy.com

 
Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Dow Pharmaceutical Sciences

Dow Pharmaceutical Sciences is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Chinook Therapeutics

Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.

Bio Essence Corp

Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kythera Biopharmaceuticals, Inc.

Kythera Biopharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.